LAMR Q4 2025 Earnings Analysis

And I'm Jordan. Today we're diving into Lamar Advertising's Q4 2025 results - that's ticker LAMR for those following along. Before we get started though, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Well Alex, this was actually a pretty solid beat across the board. They exceeded their revised full-year guidance for AFFO - that's Adjusted Funds From Operations, which is key for REITs like Lamar. But what really stood out was December's performance - they grew acquisition-adjusted revenue almost 6% that month, which gave them serious momentum heading into 2026.

CEO Sean Reilly called out several strong categories - services up 12%, healthcare up 13%, and financial services up 17% in Q4. What's encouraging is that their biggest verticals are also their healthiest ones. Services represents 19% of their business and healthcare is 10.5%, so when those are growing double digits, that moves the needle.

They're projecting AFFO of $8.50 to $8.70 per share for 2026, which represents about 4% growth at the midpoint. But here's what's really impressive - they're targeting consolidated operating margins of over 47%, which would be the best in company history. That shows they're not just growing revenue, they're doing it efficiently.

Absolutely. Political was actually a headwind in 2025 - down about $11 million versus 2024. But Reilly pointed out this should reverse in 2026, calling it a potential $12-14 million tailwind. The thing about political advertising is it breaks late - usually September through November - so it doesn't show up in their current bookings yet.

This is actually a fascinating regulatory change story, Alex. The FDA modified rules around drug advertising disclosures. Previously, if you mentioned what a drug treats, you had to list all the potential side effects - you know, those rapid-fire disclaimers we hear on TV. Now, pharma companies can just show the drug name, company name, some pretty pictures, and say "call your doctor" without the lengthy disclaimers.

Exactly. Plus, there's a company called Crossix that's developed attribution studies specifically for outdoor advertising, helping pharma companies prove ROI. Reilly seemed genuinely excited about this opportunity, mentioning pharma multiple times during the call.

Right, they're aggressively expanding digital. They added 111 digital units in Q4, ending with 5,553 total operating digital billboards. Digital now represents 33.7% of their business in Q4, up from 31.6% for the full year. And here's the key metric - same-store digital revenue grew 3.7%, showing advertisers really value that flexibility.

They're acquisition machines, Alex. Closed 50 deals in 2025 for $191 million total, and they're already off to a hot start in 2026 - seven acquisitions since January 1st for $40 million. Reilly expects at least $200 million in acquisition spending this year. Their balance sheet is in great shape with leverage at just 2.92x, well below their target range.

UPREIT structures let them do tax-efficient acquisitions where sellers can exchange their properties for operating partnership units rather than cash, deferring capital gains taxes. It's the first time anyone in the outdoor advertising space has done this, which could open up more acquisition opportunities with sellers who want tax efficiency.

Their Atlantic and Southwest regions showed relative strength, while the Northeast was weaker. They also mentioned upcoming World Cup benefits - though at only $3-4 million incremental revenue, it's nice but not needle-moving for a company doing over $2 billion in revenue.

Reilly seemed pretty sanguine about it, basically saying it's "steady as she goes" for the industry. He noted that Clear Channel's management team is staying in place, and their financial cleanup probably won't require asset sales, so no immediate acquisition opportunities there.

Growth cadence was a big question. Reilly suggested Q1 might come in slightly below guidance implies, but they expect momentum to build throughout the year. That's partly because political advertising breaks late, and partly because their current bookings look solid but conservative.

This feels like a company hitting its stride, Alex. They're achieving record margins, expanding digital aggressively, have a fortress balance sheet for acquisitions, and are benefiting from some nice regulatory tailwinds in pharma. The 4.8% dividend yield doesn't hurt either. The outdoor advertising business has proven remarkably resilient - local advertisers keep spending, and they're gaining share in national accounts.

The usual suspects - economic downturn affecting ad spending, rising interest rates impacting their debt costs, and competition from digital advertising platforms. But their local focus provides some defensiveness, and the digital billboard expansion keeps them relevant in a changing media landscape.

Agreed. Before we wrap up though, I want to remind everyone that everything we've discussed today is AI-generated analysis for educational purposes only. Past performance doesn't guarantee future results, and please do your own due diligence before making any investment decisions.

See you next time on Beta Finch. ---